Home
About Us
Overview
Strategy
Technology and IP
R & D Pipeline
Management
Board
Scientific Advisors
History
Collaborations and Partners
Scientific Publications
Careers
Investors
Overview
Corporate Governance
Financial Reports
News Releases / Presentations
Shareholder Information
Share Price Information
Newsletters
Investor Contacts
Pharmaceuticals
Overview
Drug Delivery
TPM
Insulin
Oxycodone
Lidocaine
Diclofenac
Tretinoin
Nutraceuticals
Overview
Dietary Supplements
Functional Foods
Personal Care
Personal Care Products
Elixia Skincare Range
Investors
Overview
Corporate Governance
Financial Reports
News Releases / Presentations
Shareholder Information
Share Price Information
Newsletters
Investor Contacts
News Releases / Presentations
2013
TEST ITEM
2013 May 22 Phosphagenics Newsletter May 2013
AGM 2013 Result of Resolutions
2013 May 17 POH CEO Presentation
2013 May 14 Phosphagenics Signs Research Agreement with the Agricultural Research Service
2013 May 09 Appendix 3Y Change in Directors Interest
2013 May 07 Appendix 3Y Change of Directors Interest
2013 Apr 24 Appendix 3Y Change of Directors Interest
2013 Apr 15 AGM and proxy
2013 Apr 15 Annual Report 2012
2013 Apr 15 Phosphagenics Partner Themis Completes Supply Agreement with Novartis for TPM/Diclofenac Gel
2013 Apr 05 Phosphagenics Oxycodone Patch Resumes Clinical Development
2013 Apr 02 Phosphagenics Extends Agreement with Japanese Partner
2013 Mar 25 Oxymorphone Patch Meets Phase 1 End Points
2013 Feb 20 Phosphagenics Further Expands Pain Portfolio
2013 Feb 11 Phosphagenics Oxycodone Patch Update
2013 Feb 01 Phosphagenics Newsletter February 2013
Jan 2013 PhillipCapital Report on POH
Jan 2013 PhllipCapital Biotech Overview
2013 Jan 16 Phosphagenics Initiates Clinical Program with Oxymorphone TPM Patch
December 2012 Appendix 4E and Audited Financial Report
2012
TEST ITEM
Macquarie Report on POH Dec 2012
Nomura Initiation Report on POH Dec 2012
2012 Dec 05 Phosphagenics to Supply Firming Cream to GNC
2012 Dec 03 Oxycodone Patch Update Development Program and Product Expansion
2012 Nov 15 Reconciliation - Non-Quoted Conditional Rights
2012 Oct 31 Phosphagenics in Joint Venture to Supply TPM Equine Supplements to Global Market
2012 Oct 30 Phosphagenics Licenses TPM Platform to Indian Pharmaceutical Company
2012 Oct 10 Presentation by CEO at Macquarie Emerging Healthcare Conference Sydney
2012 Sep 26 Phosphagenics Newsletter September 2012
Bell Potter re POH Sept 2012
2012 Aug 20 Appendix 4D Report and Financial Report for Half Year ended 30 June 2012
2012 Aug 01 Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
2012 June 29 Phosphagenics to Develop Racehorse Supplements
2012 June 15 Australian Life Science Investment Showcase - presentation in New York
2012 June 07 Expiry Non-Quoted ESOP Options - POHAQ
2012 June 05 Phosphagenics’ Further Refinements to Oxycodone Patch Design
2012 May 24 POH - AGM Chairman's Address and CEO Presentation
AGM 2012 Result of Resolutions
2012 May 23 CEO Presentation - Bell Potter Life Sciences Conference
2012 May 23 Phosphagenics Engages Labtec for Final Patch Design
2012 May 21 Phosphagenics to Launch BodyShaper in UK - Boots
2012 May 08 Phosphagenics Adds David Jones as Retail Partner for Elixia Products
2012 May 03 App3B - Exercise Options - Reconciliation Non-listed security
2012 Apr 20 Annual Report and Notice of AGM
2012 Apr 04 License Agreement with Intas Pharmaceuticals
2012 Mar 22 Substantial Shareholder Notice Form 604 Orbis
2012 Mar 19 POH Bell Potter Review
2012 Mar 15 Change in Substantial Holding Form 604 ORBIS
2012 Mar 15 Korean Distribution Agreement for BioElixia
2012 Mar 05 Phosphagenics Signs Agreement with Japanese Pharmaceutical Company
2012 Mar 02 Substantial Shareholder Notice Form 604 ORBIS
2012 Mar 02 SandP Indices - March Quarterly Rebalance
2012 Feb 24 Notice of Ceasing to be Substantial Holder Form 605
2012 Feb 17 Substantial Shareholder Notice Form 604
2012 Feb 15 Phosphagenics Delivers Further Positive Oxycodone Patch Trial Results
2012 Jan 31 Substantial Shareholding Notices - Form 605 and Form 604
2011
TEST ITEM
2011 Dec 14 December 2011 eNewsletter and Placement of Shares
2011 Dec 09 General Meeting Results and CEO Presentation
2011 Nov 28 Appendix 3Y - Change of Director's Interest Notices (3)
2011 Nov 21 Phosphagenics on Track - Pivotal TPM Oxycodone Patch Trials Begin
2011 Nov 16 Share Purchase Plan - Quotation of Shares and Cheque Refunds
2011 Nov 14 SPP Closes Heavily Oversubscribed
2011 Nov 04 Notice of General Meeting 9 Dec and Proxy Form
2011 Nov 02 Phosphagenics Licenses Diclofenac Gel for Indian Market
2011 Oct 28 Cleansing Notice - Placement of Shares
2011 Oct 27 Confirmation of Placement of New Shares
2011 Oct 25 Substantial Shareholder Notice Form 604
2011 Oct 24 Share Purchase Plan
2011 Oct 21 Share Purchase Plan - Notice under ASIC CO 09-425
2011 Oct 21 Phosphagenics Successful Capital Raising and SPP
2011 Oct 04 POH Investor Presentation
2011 Oct 03 Phosphagenics to Proceed with Twice Weekly Oxycodone Patch Dev
2011 Sep 20 Bell Potter Report
2011 Sep 20 CCZ Equities Research
2011 Sep 19 Phosphagenics Ready to Commence Pivotal Oxycodone Clinical Trials
2011 Sep 15 Initial Substantial Shareholder Notice
2011 Sep 14 Phosphagenics Signs Development Deal with Global Cosmetic Company
2011 Aug 26 Change in Substantial Shareholding
2011 June Half Yearly Appendix 4D and Financial Report
2011 Aug 23 New National Stockist for Elixia Personal Care Product Range
2011 Aug 16 RBS Morgans - POH Improving the complexion
2011 July 06 Phosphagenics Signs Major Distribution Agreement for Asia
2011 July 04 Change of Director's Interest Appendix 3Y
2011 Jun 28 Phosphagenics on track to reach $1m target for personal care products
2011 May 31 AGM CEO presentation
2011 05 31 AGM 2011 Resolution Results
2011 05 26 Life Sciences Conference presentation by Dr Esra Ogru
2011 May 23 Phosphagenics and 3M Collaborate to Improve Oxycodone Patch
2011 May 17 Phosphagenics to Launch BodyShaper Cellulite Contour Creme
2011 May 05 Southern Cross Equities - Phosphagenics Research Report
2011 May 05 Alpha Securities - Phosphagenics Research Report
2011 Apr 29 Annual Report and Notice of AGM/Proxy Form
2011 Apr 20 Phosphagenics Moves into Lucrative Hair Care Market
2011 Apr 11 Phosphagenics to Launch New Cellulite Cosmetic
2011 Apr 07 Phosphagenics New Elixia Skincare Products to Launch on Shopping TV
2011 Apr 04 Phosphagenics Collaboration to Develop Anti-acne Drug
2011 Mar 21 Section 708A Cleansing Notice re new securities
2011 Mar 18 Appendix 3B Notice - Equity Raising
2011 Mar 16 Phosphagenics Equity Raising Update
2011 Mar 14 Phosphagenics to raise $5.6 million to fund clinical trials
2011 Mar 03 Phosphagenics to Partner with Agriculture Company for Australian and New Zealand Market
2010
TEST ITEM
2010 Dec 30 Share Trading Policy
2010 Nov 16 Collaboration with 3M to Develop Pain Patch
2010 Oct 27 IP Management Commercialisation presentation by Kathryn Harrison
2010 Oct 19 Phosphagenics on track to commercialise anti-fat peptide using TPM™ technology
2010 Oct 13 TPM oxycodone - preparation - pain patch manufacturing after positive results
2010 Sept 2 Phosphagenics Exercises Option to Licence AOD9604 to Develop Topical Cellulite Product
August 2010 Southern Cross Phosphagenics Report
2010 Aug 24 Phosphagenics Appoints Three New Non-Executive Directors to Boost its Commercial Transformation
2010 July 21 BioBusiness Asia 2010 presentation by Dr Ogru
2010 June 30 Pain Patch Technology Moves Forward
2010 June 8 BioMelbourne Network presentation by Dr Esra Ogru
2010 May 31 Adoption of New Constitution
2010 June 01 Appendix 3Z Final Director's Interest Notice
AGM 2010 Resolution Results
2010 May 31 AGM Chairman address and CEO presentation
May 2010 Southern Cross Phosphagenics Report
May 2010 Phosphagenics Company Presentation
2010 May 4 Notice of Annual General Meeting 31May and documentation
2010 Apr 29 Joint CEO Appointment - Dr E Ogru
2010 Apr 23 Annual Report 2009
2010 April 15 Chairman to Retire in May
2010 April 12 Phosphagenics Appoints Southern Cross as Corporate Advisor
2010 Mar 31 Phosphagenics Signs Global Agreement for Use of Transdermal Insulin in Companian Animals
Elixia Launch Sydney 23 March 2010 presentation by Dr Esra Ogru
2010 Mar 23 Phosphagenics and The Quigley Corporation Form JV to Develop and Market OTC Products
2010 Feb 03 Phosphagenics Launches Australian Skincare Products
2010 Feb 01 Positive Results Phase 1B Transdermal Oxycodone Patch
2010 Jan 13 Phosphagenics to present at OneMedForum 2010 and corporate presentation
2009
TEST ITEM
2009 Dec 17 Insulin Patch on Track for Clinical Trials
2009 Dec 15 Metabolic Syndrome Trial Results
2009 Dec 02 Oxycodone Phase 1B Patch Human Trial
2009 Nov 04 Major US Launch for Phosphagenics' Personal Care Products
2009 Oct 05 Share Purchase Plan
2009 Sep 15 Transdermal Oxycodone Matrix Patch Phase 1 Trial Successful Completion
2009 Sep 09 Phosphagenics to commence Phase 2/3 Topical Diclofenac Trial
2009 Aug 18 SPP - Variation to underwriting commitment
2009 August 13 Share Purchase Plan
2009 August 13 Metabolic Pharmaceuticals Agreement
2009 July 20 Phosphagenics to Launch Premium Cosmetics Products in USA in partnership with Metier Tribeca
2009 June 29 Phosphagenics Announces the Successful Completion of a Phase 1 Clinical Trial using TPM/Oxycodone
2009 June 19 Phosphagenics signs agreement with CSL to evaluate TPM technology
2009 May 29 Phosphagenics Announces Completion of Transdermal Patch Prototypes
2009 May 29 AGM Chairman address and COO presentation
2009 May 20 Phosphagenics Bio International Convention Presentation
2009 April 30 Retinoic Acid Trial Demonstates Increased Delivery and Reduced Irritation
2009 Apr 14 Annual Report 2008 and 2009 AGM documentation
2009 Feb 23 - Phosphagenics phase 1 topical Diclofenac study
2009 Feb 20 Appointment of Dr Esra Ogru as Chief Operating Officer and Dr Paul Gavin as Vice President, Research & Development
2009 Jan 28 Acquired Intangible Asset Valuation Review
2009 Jan 06 - Insulin trial on type 1 diabetic patients completed
2008
TEST ITEM
2008 Phosphagenics Annual Report
2008 Dec 08 - Positive clinical trial results for transdermal lidocaine
2008 Nov 12 - Transdermal diclofenac enters phase 1 clinical trial in humans
2008 Nov 05 - Metabolic syndrome phase 2 clinical trial recruitment completed
2008 Oct 07 Phosphagenics presentation at the annual pain therapeutics summit
2008 Sep 23 - Phosphagenics announces initiation of phase 1 clinical trial in humans for its transdermal lidocaine
2008 May 23 - AGM Results
2008 May 23 - AGM chairman's and ceo's addresses
2008 Apr 30 - Phosphagenics reports positive pre-clinical results for targeted delivery of lidocaine
2008 Mar 19 - Phosphagenics initiates its phase 2 clinical trial in type 1 diabetes
2008 Feb 19 - Phosphagenics initiates clinical trial for its topical retinoic acid